Polymorphisms in the angiotensin converting enzyme gene and growth in the first year of life

P C Hindmarsh1, C H Rodeck, S E Humphries

  • 1Centre for Human Growth and Maturation, Institute of Child Health, London, UK. p.hindmarsh@ucl.ac.uk

Annals of Human Genetics
|October 13, 2006
PubMed

Insights

The angiotensin converting enzyme (ACE) I/I genotype is linked to increased weight and body mass index in infants, showing catch-up growth. The ACE D/D genotype is associated with a higher proportion of small-for-gestational-age infants.

Area of Science:

  • Genetics
  • Pediatrics
  • Cardiovascular Disease Risk

Background:

  • Abnormal fetal and infant growth patterns are linked to adult cardiovascular disease.
  • Catch-up growth in infancy is associated with type 2 diabetes, while lack of it is linked to hypertension.
  • The influence of genetic factors on early growth and blood pressure requires further investigation.

Purpose of the Study:

  • To investigate the association between angiotensin converting enzyme (ACE) gene polymorphisms and early human growth patterns.
  • To explore the role of ACE genotype in infant size at birth and at one year of age.
  • To determine if ACE genotype influences catch-up growth in infancy.

Main Methods:

  • Genotyping of the ACE gene (I/D alleles) in cord blood samples from 530 Caucasian infants.
  • Measurement of infant size at birth and at one year of age.
  • Statistical analysis including regression models to assess genotype-phenotype associations.

Main Results:

  • The ACE I/I genotype was significantly associated with higher weight, body mass index, and mid-arm circumference at one year.
  • Infants with the I/I genotype showed significant catch-up growth in weight, body mass index, and mid-arm circumference compared to the D/D group.
  • The ACE D/D genotype was associated with a greater proportion of infants born small for gestational age.

Conclusions:

  • The ACE I/I genotype is linked to accelerated postnatal growth and higher body mass index in the first year of life.
  • The ACE D/D genotype is associated with a higher incidence of being small for gestational age.
  • Genotype, sex, and socioeconomic status independently influence infant growth, highlighting the need for integrated causality models.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...